XBiotech Inc. (NASDAQ:XBIT - Get Free Report) passed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $2.94 and traded as low as $2.57. XBiotech shares last traded at $2.64, with a volume of 73,201 shares trading hands.
XBiotech Stock Down 4.3%
The firm's 50-day moving average is $2.94 and its 200-day moving average is $3.69. The company has a market cap of $80.49 million, a PE ratio of -2.44 and a beta of 0.97.
XBiotech (NASDAQ:XBIT - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter.
Institutional Investors Weigh In On XBiotech
Hedge funds and other institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. grew its holdings in XBiotech by 68.2% in the fourth quarter. JPMorgan Chase & Co. now owns 14,624 shares of the biopharmaceutical company's stock worth $58,000 after purchasing an additional 5,930 shares during the period. Virtu Financial LLC bought a new position in shares of XBiotech in the fourth quarter worth approximately $58,000. Hsbc Holdings PLC bought a new position in shares of XBiotech in the first quarter worth approximately $52,000. Bank of America Corp DE lifted its stake in shares of XBiotech by 42.0% in the fourth quarter. Bank of America Corp DE now owns 19,888 shares of the biopharmaceutical company's stock worth $79,000 after buying an additional 5,887 shares in the last quarter. Finally, Nuveen LLC bought a new position in shares of XBiotech in the first quarter worth approximately $81,000. Hedge funds and other institutional investors own 55.70% of the company's stock.
About XBiotech
(
Get Free Report)
XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.
See Also
Before you consider XBiotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and XBiotech wasn't on the list.
While XBiotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
